CIRM Funded Clinical Trials

Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients


Mehrdad Abedi
Disease Area: 
HIV-related Lymphoma
Investigator:
CIRM Grant:
Award Value:
$8,414,265
Trial Stage: 
Phase 1/2
Trial Status: 
Suspended
Targeted Enrollment:
18
ClinicalTrials.gov ID:
Details: 

A team at UC Davis is taking a patient’s blood forming stem cells and inserting three anti-HIV genes into them and then returning them to the individual to help rebuild their immune system. The anti-HIV genes are then passed on to all new immune system cells, which makes them resistant to HIV. Because AIDS-related lymphoma is linked to the constant immune cell stimulation caused by HIV infection, getting rid of the virus should prevent return of the cancer.

Design: 

Open label, single arm study.

Goal: 

Safety. Efficacy - immune reconstitution, viral load and HIV status.

Updates: 

This study has suspended participant recruitment.